Clinical Trial Update: Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) [Phase 2]

View source ↗

Summary

Merck's Phase 2 trial MK-6024-016 evaluating alternate dosing in adults with metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatotic Liver Disease
• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• MK-6024

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED